Your browser doesn't support javascript.
loading
Identification and characterization of a MAPT-targeting locked nucleic acid antisense oligonucleotide therapeutic for tauopathies.
Easton, Amy; Jensen, Marianne L; Wang, Congwei; Hagedorn, Peter H; Li, Yuwen; Weed, Michael; Meredith, Jere E; Guss, Valerie; Jones, Kelli; Gill, Martin; Krause, Carol; Brown, Jeffrey M; Hunihan, Lisa; Natale, Joanne; Fernandes, Alda; Lu, Yifeng; Polino, Joe; Bookbinder, Mark; Cadelina, Greg; Benitex, Yulia; Sane, Ramola; Morrison, John; Drexler, Dieter; Mercer, Stephen E; Bon, Charlotte; Pandya, Nikhil J; Jagasia, Ravi; Ou Yang, Tai-Hsien; Distler, Tania; Grüninger, Fiona; Meldgaard, Michael; Terrigno, Marco; Macor, John E; Albright, Charles F; Loy, James; Hoeg, Anja M; Olson, Richard E; Cacace, Angela M.
Afiliación
  • Easton A; Bristol Myers Squibb Research and Development, Cambridge, MA 02142, USA.
  • Jensen ML; Roche Pharma Research and Early Development, Therapeutic Modalities, Roche Innovation Center Copenhagen, Hørsholm DK 2970, Denmark.
  • Wang C; Roche Pharma Research and Early Development, Neuroscience and Rare Disease Discovery and Translational Area, Roche Innovation Center Basel, 4070 Basel, Switzerland.
  • Hagedorn PH; Roche Pharma Research and Early Development, Therapeutic Modalities, Roche Innovation Center Copenhagen, Hørsholm DK 2970, Denmark.
  • Li Y; Bristol Myers Squibb Research and Development, Cambridge, MA 02142, USA.
  • Weed M; Bristol Myers Squibb Research and Development, Cambridge, MA 02142, USA.
  • Meredith JE; Bristol Myers Squibb Research and Development, Cambridge, MA 02142, USA.
  • Guss V; Bristol Myers Squibb Research and Development, Cambridge, MA 02142, USA.
  • Jones K; Bristol Myers Squibb Research and Development, Cambridge, MA 02142, USA.
  • Gill M; Bristol Myers Squibb Research and Development, Cambridge, MA 02142, USA.
  • Krause C; Bristol Myers Squibb Research and Development, Cambridge, MA 02142, USA.
  • Brown JM; Bristol Myers Squibb Research and Development, Cambridge, MA 02142, USA.
  • Hunihan L; Bristol Myers Squibb Research and Development, Cambridge, MA 02142, USA.
  • Natale J; Bristol Myers Squibb Research and Development, Cambridge, MA 02142, USA.
  • Fernandes A; Bristol Myers Squibb Research and Development, Cambridge, MA 02142, USA.
  • Lu Y; Bristol Myers Squibb Research and Development, Cambridge, MA 02142, USA.
  • Polino J; Bristol Myers Squibb Research and Development, Cambridge, MA 02142, USA.
  • Bookbinder M; Bristol Myers Squibb Research and Development, Cambridge, MA 02142, USA.
  • Cadelina G; Bristol Myers Squibb Research and Development, Cambridge, MA 02142, USA.
  • Benitex Y; Bristol Myers Squibb Research and Development, Cambridge, MA 02142, USA.
  • Sane R; Bristol Myers Squibb Research and Development, Cambridge, MA 02142, USA.
  • Morrison J; Bristol Myers Squibb Research and Development, Cambridge, MA 02142, USA.
  • Drexler D; Bristol Myers Squibb Research and Development, Cambridge, MA 02142, USA.
  • Mercer SE; Bristol Myers Squibb Research and Development, Cambridge, MA 02142, USA.
  • Bon C; Roche Pharma Research and Early Development, Neuroscience and Rare Disease Discovery and Translational Area, Roche Innovation Center Basel, 4070 Basel, Switzerland.
  • Pandya NJ; Roche Pharma Research and Early Development, Neuroscience and Rare Disease Discovery and Translational Area, Roche Innovation Center Basel, 4070 Basel, Switzerland.
  • Jagasia R; Roche Pharma Research and Early Development, Neuroscience and Rare Disease Discovery and Translational Area, Roche Innovation Center Basel, 4070 Basel, Switzerland.
  • Ou Yang TH; Roche Pharma Research and Early Development, pREDi Data Science, Roche Innovation Center New York, Little Falls, NJ 07424, USA.
  • Distler T; Roche Pharma Research and Early Development, Neuroscience and Rare Disease Discovery and Translational Area, Roche Innovation Center Basel, 4070 Basel, Switzerland.
  • Grüninger F; Roche Pharma Research and Early Development, Neuroscience and Rare Disease Discovery and Translational Area, Roche Innovation Center Basel, 4070 Basel, Switzerland.
  • Meldgaard M; Roche Pharma Research and Early Development, Therapeutic Modalities, Roche Innovation Center Copenhagen, Hørsholm DK 2970, Denmark.
  • Terrigno M; Roche Pharma Research and Early Development, Neuroscience and Rare Disease Discovery and Translational Area, Roche Innovation Center Basel, 4070 Basel, Switzerland.
  • Macor JE; Bristol Myers Squibb Research and Development, Cambridge, MA 02142, USA.
  • Albright CF; Bristol Myers Squibb Research and Development, Cambridge, MA 02142, USA.
  • Loy J; Bristol Myers Squibb Research and Development, Cambridge, MA 02142, USA.
  • Hoeg AM; Roche Pharma Research and Early Development, Therapeutic Modalities, Roche Innovation Center Copenhagen, Hørsholm DK 2970, Denmark.
  • Olson RE; Bristol Myers Squibb Research and Development, Cambridge, MA 02142, USA.
  • Cacace AM; Bristol Myers Squibb Research and Development, Cambridge, MA 02142, USA.
Mol Ther Nucleic Acids ; 29: 625-642, 2022 Sep 13.
Article en En | MEDLINE | ID: mdl-36090761
Palabras clave
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Tipo de estudio: Diagnostic_studies Idioma: En Revista: Mol Ther Nucleic Acids Año: 2022 Tipo del documento: Article País de afiliación: Estados Unidos
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Tipo de estudio: Diagnostic_studies Idioma: En Revista: Mol Ther Nucleic Acids Año: 2022 Tipo del documento: Article País de afiliación: Estados Unidos